Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.13 USD
-0.02 (-1.74%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $1.15 +0.02 (1.77%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 241 - 260 ( 274 total )
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Sweet Fruit from the PEACHTREE-ME-NIU Phase 3 Hits
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
First Phase 3 Results for SCS-Microinjection Platform in Early March
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Q3 Financials and Outlook: Cash Runway Covers Major Q1 Catalyst
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Cash Covers Pipeline Progress and Multiple Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
The Week Ahead in Life Sciences: Upcoming Events for the Week of Aug 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Clearside Biomedical, Inc.
Industry: Unclassified
June and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Q1 Financial Update: Runway into Q4:18 Covers Several Key Catalysts; Reiterate OUTPERFORM and $27 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
May and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Results from the Phase 1/2 HULK Trial on Track for H2:17 Release; Reiterate OUTPERFORM and $27 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Corporate Update: We See Increasing Due Diligence in Front of Potential Catalysts in H2:17; Reiterate OUTPERFORM and $27 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
April and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Q4/FY16, Several Clinical Catalysts Over the Next 12- Months, Reiterate OUTPERFORM but Reducing PT to $27 for Slow PEACHTREE Enrollment Causing Delay
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
March and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Initiation of Zuprata Phase 3 for ME-RVO and Model Update; Reiterate OUTPERFORM and $28 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
February and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
January and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
2017 Preview: Our Top Picks, and Key Data Readouts and Launches Up Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Time to Buy: Unwarranted Stock Weakness Based on Investor Sentiment--Not Fundamentals; Reiterate OUTPERFORM and $28 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L